QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF For Our Patients Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Van Tassell, B. W Articles by Munger, M. A Search for Related Content PubMed PubMed Citation Articles by Van Tassell, B. W Articles by Munger, M. A

NEW DRUG DEVELOPMENTS

Aliskiren for Renin Inhibition: A New Class of Antihypertensives

Fellow, Experimental Cardiovascular Pharmacotherapy, Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT

Mark A Munger, PharmD FCCP

Professor, Pharmacotherapy and Internal Medicine; Associate Dean, College of Pharmacy, University of Utah

Reprints: Dr. Van Tassell, University of Utah, 30 South, 2000 East, Rm #258, Salt Lake City, UT 84112, fax 801/585-6160, benjamin. vantassell{at}pharm.utah.edu

OBJECTIVE: To review the safety, efficacy, pharmacology, pharmacokinetics, and drug interactions of aliskiren for the treatment of mild-to-moderate hypertension.

DATA SOURCES: A literature search was conducted using MEDLINE (1966-January 2007), International Pharmaceutical Abstracts (1970-January 2007), and Cochrane database (2006) for the key words aliskiren or SPP100. References of selected articles were also reviewed. Abstract data were included only in the absence of significant published data.

STUDY SELECTION AND DATA EXTRACTION: Available English-language data from reviews, abstracts, and clinical trials were selected. For review of efficacy, randomized controlled trials were preferred.

DATA SYNTHESIS: Aliskiren is a renin inhibitor, the first in a new class of antihypertensives. As renin catalyzes the rate-limiting step of the renin-angiotensin system (RAS), renin inhibition may offer a theoretical advantage over other RAS inhibitors, such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs). In short-term clinical trials (8 wk) of subjects with mild-to-moderate hypertension, single daily doses of aliskiren 150-300 mg produced significant systolic and diastolic blood pressure reduction similar to that achieved with ACE inhibitors and ARBs, with placebo-like tolerability, without an elevation in heart rate or evidence of tolerance.

CONCLUSIONS: Aliskiren appears to be a safe and effective treatment option in mild-to-moderate hypertension. Although long-term outcome data have not been published, aliskiren is a promising option for RAS inhibition.

Key Words: aliskiren, hypertension, renin inhibitor

Published Online, March 6, 2007. www.theannals.com, DOI 10.1345/aph.1H549

THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE UNIVERSAL PROGRAM NUMBER: 407-000-07-011-H01

This article has been cited by other articles:

				K. K. Daugherty Aliskiren Am. J. Health Syst. Pharm., July 15, 2008; 65(14): 1323 - 1332. [Abstract] [Full Text] [PDF]

				N. D.L. Fisher, A.H. Jan Danser, J. Nussberger, W. P. Dole, and N. K. Hollenberg Renal and Hormonal Responses to Direct Renin Inhibition With Aliskiren in Healthy Humans Circulation, June 24, 2008; 117(25): 3199 - 3205. [Abstract] [Full Text] [PDF]

				Y. Bukhtiyarov, M. Zecher, R. Panemangalore, Z. Wu, J. G. Bruno, J. Yuan, Z. Xu, L. W. Dillard, G. M. McGeehan, R. K. Harrison, et al. Cloning, Characterization and Site-Directed Mutagenesis of Canine Renin J. Biochem., December 1, 2007; 142(6): 671 - 680. [Abstract] [Full Text] [PDF]